BioWorld Today: News To Note- Immune Design Corp.
June 13, 2013 - BioWorld Today
Immune Design Corp., of Seattle, the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research signed a collaboration agreement to advance cancer immunotherapy research. Specifically, the partnership will focus on clinical trials to test combinations of immunotherapies, including two investigational drugs from Immune Design’s pipeline. The Ludwig Institute and CRI will conduct studies, while Immune Design will provide the products from its pipeline, which includes a synthetic Toll-like receptor 4 agonist adjuvant (glucopyronosyl lipid A, or GLA) and LV305, a lentivector-based vaccine product candidate. Financial terms were not disclosed.